Covestor’s Travere Therapeutics TVTX Stock Holding History

Covestor’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1K	Sell	9 -12	-57%	-$733	﹤0.01%	2216
2026 Q2	$1K	Buy	21 +15	+250%	+$665	﹤0.01%	2358
2026 Q1	$0	Hold	6	–	–	﹤0.01%	2782
2025 Q4	$0	Hold	6	–	–	﹤0.01%	2749
2025 Q3	$0	Hold	6	–	–	﹤0.01%	2789
2025 Q2	$0	Sell	6 -1	-14%	-$17	﹤0.01%	2771
2025 Q1	$0	Hold	7	–	–	﹤0.01%	2742
2024 Q4	$0	Sell	7 -4	-36%	-$71	﹤0.01%	2753
2024 Q3	$0	Hold	11	–	–	﹤0.01%	2783
2024 Q2	$0	Sell	11 -1	-8%	-$7	﹤0.01%	2773
2024 Q1	$0	Hold	12	–	–	﹤0.01%	2758
2023 Q4	$0	Buy	12 +5	+71%	+$36	﹤0.01%	2733
2023 Q3	$0	Sell	7 -1	-13%	-$14	﹤0.01%	2730
2023 Q2	$0	Sell	8 -1	-11%	-$18	﹤0.01%	2669
2023 Q1	$0	Hold	9	–	–	﹤0.01%	2603
2022 Q4	$0	Hold	9	–	–	﹤0.01%	2623
2022 Q3	$0	Sell	9 -2	-18%	-$52	﹤0.01%	2624
2022 Q2	$0	Sell	11 -3	-21%	-$75	﹤0.01%	2376
2022 Q1	$0	Sell	14 -3	-18%	-$80	﹤0.01%	2450
2021 Q4	$1K	Buy	+17	New	+$479	﹤0.01%	1963

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Covestor's TVTX Position: Q3 2026 in Review

Covestor reduced its Travere Therapeutics (TVTX) stake by 57% in Q3 2026, selling an estimated $733 and leaving 9 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Covestor first reported a position in TVTX in Q4 2021 and has held it in 20 quarters since. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Covestor held 9 shares of Travere Therapeutics worth $1K as of Q3 2026.
Covestor sold 12 Travere Therapeutics shares in Q3 2026, an estimated $733.
Travere Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2216 holding.
Covestor first reported a position in Travere Therapeutics in Q4 2021 and has held it in 20 quarters since.
158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.